Peter Martin, MD

Peter Martin, MD, discusses the role of BTK inhibitors in the treatment of mantle cell lymphoma.

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Experts on follicular lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

Experts on follicular lymphoma discuss first-line treatment options available for patients.

Peter Martin, MD, discusses the importance of designing clinical trials for real-world utility in mantle cell lymphoma.

Peter Martin, MD, discusses the role of maintenance therapy with rituximab in mantle cell lymphoma.

Peter Martin, MD, discusses the findings of a real-world analysis of clinical outcomes in mantle cell lymphoma.

Peter Martin, MD, discusses the rationale to evaluate real-world outcomes in mantle cell lymphoma.

Peter Martin, MD, discusses selecting treatment for patients with high-risk mantle cell lymphoma.

Peter Martin, MD, discusses selecting among BTK inhibitors for the treatment of patients with mantle cell lymphoma.

Peter Martin, MD, discusses treatment considerations for patients with mantle cell lymphoma.

Peter Martin, MD, discusses the importance of developing novel therapies in mantle cell lymphoma.

Peter Martin, MD, discusses the potential role of LOXO-305 in mantle cell lymphoma.

Peter Martin, MD, discusses potential combination regimens with BTK inhibitors in mantle cell lymphoma.

Peter Martin, MD, discusses potential drug-drug interactions with BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Peter Martin, MD, discusses the frontline treatment landscape of mantle cell lymphoma.